Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04041609




Registration number
NCT04041609
Ethics application status
Date submitted
12/07/2019
Date registered
1/08/2019
Date last updated
25/07/2023

Titles & IDs
Public title
LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
Scientific title
A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects With Chronic Sinusitis (LANTERN Study)
Secondary ID [1] 0 0
2018-004621-89
Secondary ID [2] 0 0
LYR-210-2018-002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Sinusitis 0 0
Chronic Rhinosinusitis (Diagnosis) 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LYR-210
Other interventions - Sham comparator

Experimental: LYR-210 (Low Dose) - In-office bilateral placement of the LYR-210 drug depot (mometasone furoate low dose) in the middle meatus

Experimental: LYR-210 (High Dose) - In-office bilateral placement of the LYR-210 drug depot (mometasone furoate high dose) in the middle meatus

Sham comparator: Sham Procedure - In-office bilateral sham procedure


Treatment: Drugs: LYR-210
A single administration of LYR-210 depot

Other interventions: Sham comparator
Sham comparator
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline (CFBL) in Chronic Sinusitis Symptom Scores at Week 4
Timepoint [1] 0 0
Week 4
Secondary outcome [1] 0 0
Change From Baseline in the 22-item Sino-nasal Outcome Test (SNOT-22) Total Score at Week 24
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
CFBL in Chronic Sinusitis Symptom Scores at Week 24
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Participants With Improved Bilateral Zinreich Score at Week 24
Timepoint [3] 0 0
Week 24
Secondary outcome [4] 0 0
The Number of Participants With Treatment-related Adverse Events for up to 24 Weeks
Timepoint [4] 0 0
24 weeks
Secondary outcome [5] 0 0
Plasma Drug Concentrations of MF at Week 4
Timepoint [5] 0 0
4 Weeks
Secondary outcome [6] 0 0
Plasma Drug Concentrations of MF at Week 12
Timepoint [6] 0 0
12 weeks

Eligibility
Key inclusion criteria
* Diagnosis of CS.
* Two trials of medical treatments for CS in the past.
* Minimum CS symptom score.
* Ability to tolerate topical anesthesia.
* Has been informed of the nature of the study and has provided written informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.
* Agrees to comply with all study requirements.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Have undergone previous sinus surgery.
* Pregnant or breast feeding.
* Known history of hypersensitivity or intolerance to corticosteroids.
* History or clinical evidence or suspicion of invasive fungal sinusitis, allergic fungal rhinosinusitis, or atrophic rhinitis.
* Known history of hypothalamic pituitary adrenal axial dysfunction or having a morning serum cortisol level at screening outside of the normal range.
* Had dental procedure/implant on maxillary dentition within 4 weeks of the Screening visit.
* Past or present functional vision in only one eye.
* Has cataracts
* Past, present, or planned organ transplant or chemotherapy with immunosuppression.
* Currently participating in an investigational drug or device study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/05/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/02/2021
Sample size
Target
Accrual to date
Final
71
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Brisbane and Woman's Hospital - Brisbane
Recruitment hospital [2] 0 0
Monash Health - Clayton
Recruitment hospital [3] 0 0
The ENT Centre - Hornsby
Recruitment hospital [4] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
- Brisbane
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
2077 - Hornsby
Recruitment postcode(s) [4] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Wien
Country [2] 0 0
Czechia
State/province [2] 0 0
Czech Republic
Country [3] 0 0
Czechia
State/province [3] 0 0
Prague
Country [4] 0 0
Czechia
State/province [4] 0 0
Brno
Country [5] 0 0
New Zealand
State/province [5] 0 0
Auckland
Country [6] 0 0
New Zealand
State/province [6] 0 0
Christchurch
Country [7] 0 0
New Zealand
State/province [7] 0 0
Hamilton
Country [8] 0 0
New Zealand
State/province [8] 0 0
Papatoetoe
Country [9] 0 0
New Zealand
State/province [9] 0 0
Tauranga
Country [10] 0 0
New Zealand
State/province [10] 0 0
Wellington
Country [11] 0 0
Poland
State/province [11] 0 0
Katowice
Country [12] 0 0
Poland
State/province [12] 0 0
Kraków
Country [13] 0 0
Poland
State/province [13] 0 0
Warszawa
Country [14] 0 0
Poland
State/province [14] 0 0
Wroclaw

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Lyra Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects with Chronic Sinusitis.
Trial website
https://clinicaltrials.gov/study/NCT04041609
Trial related presentations / publications
Cervin A, Rimmer J, Wrobel A, Abelak Y, Brayton L, Kuang Y. Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study. Int Forum Allergy Rhinol. 2022 Feb;12(2):147-159. doi: 10.1002/alr.22883. Epub 2021 Sep 17.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04041609